U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07111572) titled 'Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis' on Aug. 01.
Brief Summary: This multicenter prospective cohort aims to evaluate whether combined changes in fecal calprotectin (FC) and fecal immunochemical test (FIT) at **Week 2 and Week 4** after initiating biologic therapy (vedolizumab or infliximab) can predict clinical response at **Week 14** and mucosal healing at **Week 52** in moderate-to-severe ulcerative colitis (UC) patients. Primary outcome: clinical remission rate at Week 14.
Study Start Date: Aug. 01
Study Type: OBSERVATIONAL
Condition:
Ulcerative Colitis (UC)
Fecal Calprotetin
FIT...